Literature DB >> 12884237

Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.

Sehwan Han1, Kyeongmee Park, Byung-Noe Bae, Ki Hwan Kim, Hong-Joo Kim, Young-Duck Kim, Hong-Yong Kim.   

Abstract

BACKGROUND AND OBJECTIVES: Altered expression of cell-cycle regulators is prevalent in clinical breast cancer. This study was performed to analyze the impact of cyclin E expression to the outcome of breast cancer together with cyclin D1 and p27Kip1.
METHODS: The correlation between cyclin D1/E and p27Kip1 expression was analyzed in tissue arrays of 175 node-negative breast cancers treated by the same chemotherapy composed of fluorouracil, cyclophosphamide, and methotrexate. Data from the immunohistochemical assays of three molecules were correlated and were analyzed with clinical outcome of the patients.
RESULTS: Cyclin E expression was observed in 48 (27.4%) of 175 breast carcinomas. Cyclin E expression was significantly increased in young age patients and poorly differentiate tumors. Expression of cyclin E was significantly increased in cyclin D1 expressing tumors (P = 0.034). p27Kip1 expression was preserved above the 50% level in 87 tumors (49.7%) and was inversely correlated with cyclin E expression (P = 0.042). Ki67 labeling index was significantly increased in cyclin E-expressing tumors (P = 0.033) and was inversely related with p27Kip1 expression. In multivariate survival analysis, cyclin E expression was significant for the prediction of poor survival of the patients.
CONCLUSIONS: Cyclin E expression was associated with poor prognosis and intimately correlated with the expression of cyclin D1 and p27Kip1. Integration of TMA technology allowed a high-throughput analysis for correlating molecular in situ findings with clinico-pathologic information. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884237     DOI: 10.1002/jso.10268

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Judith Schütte; Marijke N Boersma; Robert L Sutherland; Jason S Carroll; Elizabeth A Musgrove
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 2.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

3.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

4.  Prognostic value of cyclin E expression in breast cancer: a meta-analysis.

Authors:  Sheng Gao; Jing-Jing Ma; Cheng Lu
Journal:  Tumour Biol       Date:  2013-06-18

5.  Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Authors:  Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi
Journal:  Am J Pathol       Date:  2016-05-13       Impact factor: 4.307

Review 6.  Biomolecular features of clinical relevance in breast cancer.

Authors:  Maria Grazia Daidone; Angelo Paradiso; Massimo Gion; Nadia Harbeck; Fred Sweep; Manfred Schmitt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-17       Impact factor: 9.236

7.  Cyclin E deregulation is an early event in the development of breast cancer.

Authors:  Alexandra Shaye; Aysegul Sahin; Qiang Hao; Kelly Hunt; Khandan Keyomarsi; Isabelle Bedrosian
Journal:  Breast Cancer Res Treat       Date:  2008-12-24       Impact factor: 4.872

Review 8.  Cell cycle and no end.

Authors:  Mathewos Tessema; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2004-02-17       Impact factor: 4.064

9.  Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.

Authors:  Satu Luhtala; Synnöve Staff; Minna Tanner; Jorma Isola
Journal:  Tumour Biol       Date:  2016-01-26

10.  Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Authors:  Oluf Dimitri Røe; Adam Szulkin; Endre Anderssen; Arnar Flatberg; Helmut Sandeck; Tore Amundsen; Sten Even Erlandsen; Katalin Dobra; Stein Harald Sundstrøm
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.